Pancreatic Cancer Research

ResearcherUniversity of MichiganActive in the last 2 years

Philip A. Philip

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6513-3491; OpenAlex author ID A5011817630, A5053703913, A5072170693. Sources: ClinicalTrials.gov.

Their work

Papers
77 (first author 7, last author 11)
Trials
3
Grants
0
Labs led
2
Collaborators
211
Papers, trials and grants by year

1999: 1 trial · 2000: none · 2001: none · 2002: none · 2003: none · 2004: 2 trials · 2005: none · 2006: none · 2007: none · 2008: none · 2009: none · 2010: none · 2011: 7 papers · 2012: 4 papers · 2013: 5 papers · 2014: 5 papers · 2015: 3 papers · 2016: 4 papers · 2017: 4 papers · 2018: 4 papers · 2019: 10 papers · 2020: 7 papers · 2021: 8 papers · 2022: 3 papers · 2023: 4 papers · 2024: 5 papers · 2025: 2 papers · 2026: 2 papers

Papers 50 of 77

  1. Daraxonrasib in pancreatic cancer: When progress disrupts practice. First author DOI 10.1016/j.drudis.2026.104761↗
  2. Ranking targeted therapies in advanced pancreatic adenocarcinoma: insights from a network meta-analysis. First author DOI 10.21037/jgo-2026-0209↗
  3. Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 St… Co-author DOI 10.1200/jco-25-00746↗
  4. PCNA Inhibition Enhances the Antitumor Activity of KRAS-Targeted Therapies in Pancreatic Cancer Co-author DOI 10.64898/2025.12.06.692635↗
  5. Deciphering cellular plasticity in pancreatic cancer for effective treatments. Co-author DOI 10.1007/s10555-023-10164-5↗
  6. RCC1 regulation of subcellular protein localization via Ran GTPase drives pancreatic ductal adenocarcinoma growth. Co-author DOI 10.1016/j.canlet.2024.217275↗
  7. Body composition measurements and clinical outcomes in patients with resectable pancreatic adenocarcinoma - analysis from SWOG S1505. Co-author DOI 10.1016/j.gassur.2023.12.022↗
  8. Intratumoral Cell Neighborhoods Coordinate Outcomes in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2024.01.013↗
  9. Relacorilant plus nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma: results from the open-label RELIANT study. Co-author DOI 10.1093/oncolo/oyae210↗
  10. Molecular analysis of XPO1 inhibitor and gemcitabine-nab-paclitaxel combination in KPC pancreatic cancer mouse model. Co-author DOI 10.1002/ctm2.1513↗
  11. Targeting Cellular Metabolism With CPI-613 Sensitizes Pancreatic Cancer Cells to Radiation Therapy. Co-author DOI 10.1016/j.adro.2022.101122↗
  12. Neoadjuvant therapy for pancreatic cancer. Co-author DOI 10.1038/s41571-023-00746-1↗
  13. Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial. Co-author DOI 10.1200/jco.22.01134↗
  14. A randomized phase II study of SM-88 plus methoxsalen, phenytoin, and sirolimus in patients with metastatic pancreatic cancer treated in the second line and be… Co-author DOI 10.1002/cam4.4768↗
  15. Role of noncoding RNAs in pancreatic ductal adenocarcinoma associated cachexia. Co-author DOI 10.1152/ajpcell.00424.2022↗
  16. Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-21-3581↗
  17. Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Phase 2 Randomized Clinical Trial. Co-author DOI 10.1001/jamaoncol.2020.7328↗
  18. Targeting KRAS in pancreatic cancer: new drugs on the horizon. Co-author DOI 10.1007/s10555-021-09990-2↗
  19. Pancreatic cancer: why we must be optimistic? Co-author DOI 10.1007/s10555-021-09994-y↗
  20. Differences in Baseline Characteristics and White Blood Cell Ratios Between Racial Groups in Patients with Pancreatic Adenocarcinoma. Last author DOI 10.1007/s12029-020-00378-z↗
  21. BRCA mutations in pancreatic cancer and progress in their targeting. Last author DOI 10.1080/14728222.2021.1957462↗
  22. Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: … Co-author DOI 10.1158/1078-0432.ccr-21-1789↗
  23. Exosomal microRNA in Pancreatic Cancer Diagnosis, Prognosis, and Treatment: From Bench to Bedside. Co-author DOI 10.3390/cancers13112777↗
  24. Non-Coding RNAs in Pancreatic Cancer Diagnostics and Therapy: Focus on lncRNAs, circRNAs, and piRNAs. Co-author DOI 10.3390/cancers13164161↗
  25. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study. Co-author DOI 10.1016/s2468-1253(19)30327-9↗
  26. Clinical and immune responses to anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (EGFR BATs) in pancreatic cancer patients. Co-author DOI 10.1080/2162402x.2020.1773201↗
  27. Surgical Outcome Results From SWOG S1505: A Randomized Clinical Trial of mFOLFIRINOX Versus Gemcitabine/Nab-paclitaxel for Perioperative Treatment of Resectabl… Co-author DOI 10.1097/sla.0000000000004155↗
  28. Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/esmoopen-2020-000942↗
  29. Preclinical Assessment with Clinical Validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the Treatment of Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1158/1078-0432.ccr-19-1728↗
  30. Metastatic Pancreatic Cancer: ASCO Guideline Update. Co-author DOI 10.1200/jco.20.01364↗
  31. Calcium Release-Activated Calcium (CRAC) Channel Inhibition Suppresses Pancreatic Ductal Adenocarcinoma Cell Proliferation and Patient-Derived Tumor Growth. Co-author DOI 10.3390/cancers12030750↗
  32. Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial. Last author DOI 10.1001/jamaoncol.2019.1588↗
  33. miRNA and Gene Expression in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1016/j.ajpath.2018.10.005↗
  34. Optimizing the management of locally advanced pancreatic cancer with a focus on induction chemotherapy: Expert opinion based on a review of current evidence. Co-author DOI 10.1016/j.ctrv.2019.05.007↗
  35. Pharmacotherapeutic strategies for treating pancreatic cancer: advances and challenges. Last author DOI 10.1080/14656566.2018.1561869↗
  36. Targeting Rho GTPase effector p21 activated kinase 4 (PAK4) suppresses p-Bad-microRNA drug resistance axis leading to inhibition of pancreatic ductal adenocarc… Co-author DOI 10.1080/21541248.2017.1329694↗
  37. A Phase I/II Open-Label Multicenter Single-Arm Study of FABLOx (Metronomic 5-Fluorouracil Plus nab-Paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin) in Pat… Co-author DOI 10.1089/pancan.2019.0012↗
  38. Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma With the Introduction of New Chemotherapeutic Drugs: 10-Year Experience of a Single NCI-designat… Last author DOI 10.1097/coc.0000000000000507↗
  39. Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenoc… Co-author DOI 10.1200/jco.18.01295↗
  40. DNA-Methylation-Caused Downregulation of miR-30 Contributes to the High Expression of XPO1 and the Aggressive Growth of Tumors in Pancreatic Ductal Adenocarcin… Co-author DOI 10.3390/cancers11081101↗
  41. Adjuvant treatment of surgically resectable pancreatic ductal adenocarcinoma. First author PMID 30843899↗
  42. Retraction notice to "Increased Ras GTPase activity is regulated by miRNAs that can be attenuated by CDF treatment in pancreatic cancer cells" [Cancer Lett. 31… Co-author DOI 10.1016/j.canlet.2017.11.030↗
  43. Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. Co-author DOI 10.1016/s1470-2045(18)30098-6↗
  44. The evolution into personalized therapies in pancreatic ductal adenocarcinoma: challenges and opportunities. Last author DOI 10.1080/14737140.2018.1417844↗
  45. Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update. Co-author DOI 10.1200/jco.2018.78.9636↗
  46. Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomize… Co-author DOI 10.1001/jamaoncol.2016.5383↗
  47. Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1535-7163.mct-16-0205↗
  48. Exportin 1 (XPO1) inhibition leads to restoration of tumor suppressor miR-145 and consequent suppression of pancreatic cancer cell proliferation and migration. Co-author DOI 10.18632/oncotarget.19285↗
  49. Evolving standards of care for resected pancreatic cancer. First author PMID 28398285↗
  50. Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Tri… Co-author DOI 10.1001/jamasurg.2016.1137↗

Trials 3

  1. S0205 Gemcitabine w/ or w/o Cetuximab as First-Line Therapy in Locally Advanced Pancreas Cancer Study chair NCT00075686↗
  2. Gene Expression Profiles in Patients With Metastatic Pancreatic Cancer Study chair NCT00897741↗
  3. Combination Chemotherapy in Treating Patients With Stage III or Stage IV Pancreatic Cancer That Cannot Be Removed by Surgery Study chair NCT00004003↗

Closest collaborators

The 25 strongest of 211 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Asfar Sohail Azmi · 24 shared papers, 2011–2026 · strength 3.84
  2. Ramzi M. Mohammad · 14 shared papers, 2011–2025 · strength 1.54
  3. Amro Aboukameel · 15 shared papers, 2011–2025 · strength 1.42
  4. Md. Hafiz Uddin · 7 shared papers, 2021–2025 · strength 1.22
  5. Muhammad Wasif Saif · 5 shared papers, 2019–2026 · strength 1.02
  6. Irfana Muqbil · 8 shared papers, 2016–2024 · strength 0.96
  7. Elena Gabriela Chiorean · 7 shared papers, 2019–2024 · strength 0.93
  8. Davendra P. S. Sohal · 8 shared papers, 2016–2024 · strength 0.90
  9. Andrew M. Lowy · 9 shared papers, 2013–2024 · strength 0.86
  10. Husain Yar Khan · 6 shared papers, 2020–2025 · strength 0.85
  11. Sahar F. Bannoura · 5 shared papers, 2021–2025 · strength 0.80
  12. Bassel F. El‐Rayes · 6 shared papers, 2011–2025 · strength 0.79
  13. Anthony Frank Shields · 10 shared papers, 2011–2023 · strength 0.78
  14. Andrea Wang‐Gillam · 6 shared papers, 2017–2024 · strength 0.78
  15. Anteneh A. Tesfaye · 6 shared papers, 2018–2020 · strength 0.78
  16. Yiwei Li · 6 shared papers, 2017–2023 · strength 0.76
  17. Muhammad Shaalan Beg · 4 shared papers, 2020–2024 · strength 0.58
  18. Bin Bao · 8 shared papers, 2011–2025 · strength 0.47
  19. Mandana Kamgar · 4 shared papers, 2018–2023 · strength 0.47
  20. Howard S. Höchster · 5 shared papers, 2017–2021 · strength 0.47
  21. Ignacio Garrido‐Laguna · 4 shared papers, 2018–2024 · strength 0.43
  22. Syed Ameen Ahmad · 4 shared papers, 2013–2024 · strength 0.38
  23. Fazlul H. Sarkar · 9 shared papers, 2011–2018 · strength 0.38
  24. Dana Backlund Cardin · 4 shared papers, 2016–2024 · strength 0.38
  25. Vincent M. Chung · 3 shared papers, 2017–2024 · strength 0.36

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.